Market Intelligence, Clinical Progress, and High-Purity Reagents for Overcoming Alkylating Agent Resistance via DNA Repair Modulation.
TarMart Solution Ecosystem & Related Targets
Comprehensive reagent toolkit for MGMT drug discovery. The table below lists key products and related targets from the DNA repair and oncogenic networks.
| Component / Network | Product Description | Product Link |
|---|---|---|
| Antigen | MGMT Recombinant Protein (Wild-Type & C145A Mutant) – High purity (>95%), Endotoxin <1 EU/µg. Sequence Verified. HEK293 expressed. | View MGMT Products |
| Gene Delivery | MGMT Promise-ORF / Lentivirus – Full-length ORF for stable overexpression or resistance model construction. | View MGMT Products |
| Benchmark Ab | Anti-MGMT Recombinant Monoclonal Antibody – Positive control for Western blot / IHC validation. | View MGMT Products |
| Validator | MGMT siRNA Set – For knockdown verification and specificity controls. | View MGMT Products |
| PARP1 | PARP1 Recombinant Protein – Synthetic lethality partner; essential for combination therapy screening. | View PARP1 Products |
| MSH2 | MSH2 Recombinant Protein – Mismatch repair complex component; cross-talk with MGMT in resistance. | View MSH2 Products |
| EGFR | EGFR Recombinant Protein – Common co-alteration (EGFRvIII) in glioblastoma. | View EGFR Products |
| TP53 | TP53 Recombinant Protein – Key tumor suppressor often co-mutated in aggressive cancers. | View TP53 Products |
| Critical Assay Challenge | The TarMart Advantage (Technical Spec) |
|---|---|
| Drug Resistance Modeling (TMZ-resistant cell lines) | Lentivirus-mediated overexpression tools for creating robust temozolomide-resistant lines. |
| Enzymatic Activity Validation (O6-methylguanine transfer) | High-purity WT and C145A mutant proteins (>95%) for positive/negative enzymatic controls. |
| Inhibitor Screening (O6-benzylguanine analogs) | Sequence-verified active-site cysteine intact; theoretical MW confirmed by LC-MS. |
| Specificity Controls / False Positives | Validated siRNA sets included for rigorous target-specific knockdown verification. |
| Lack of Reliable Controls | Recombinant positive control antibodies ensuring batch-to-batch consistency for biomarker detection. |
Live MGMT R&D Tracker
Market data changes daily. Access the latest global pipeline status directly:
Global Clinical Landscape & Future Outlook
The race to overcome temozolomide (TMZ) resistance in glioblastoma (GBM) is intensifying, with a critical focus on O-6-methylguanine-DNA methyltransferase (MGMT). High intracellular expression of MGMT rapidly repairs alkylation damage, rendering standard chemotherapy ineffective. As first-generation small-molecule inhibitors (e.g., O6-benzylguanine) faced systemic toxicity (myelosuppression), the next wave of R&D is pivoting toward localized delivery, targeted protein degradation (PROTACs), synthetic lethality combinations (e.g., with PARP inhibitors), and biomarker-driven precision approaches that selectively sensitize tumor cells while sparing hematopoietic progenitors. The clinical landscape now also includes gene silencing (siRNA/shRNA) and diagnostic assays correlating MGMT protein levels with promoter methylation status.
Competitive Modality & Indication Snapshot
| Modality | Representative Players | Key Indications | Critical Assay Need (Why TarMart?) |
|---|---|---|---|
| Small Molecule Inhibitor | Various Oncology Biotechs (e.g., TriOncology, Merck) | Glioblastoma, Melanoma | Biochemical/competition assays (Need high-purity WT & C145A mutant proteins) |
| Targeted Protein Degrader (PROTAC) | Academia & Emerging Biotechs | Refractory Gliomas, TMZ-Resistant Solid Tumors | Degradation assays & PPI studies (Need specific antibodies & full-length ORF lentivirus) |
| Combination Therapy (Chemo + Inhibitor) | Major Pharmas | Refractory Cancers | Knockdown/overexpression in resistant cells (Need lentivirus & siRNA) |
| Gene Silencing (siRNA/shRNA) | Academic Institutions | Temozolomide Sensitization | Knockdown efficiency validation (Need validated siRNA sets) |
| Biomarker Assay (Diagnostic) | Diagnostic Companies | MGMT Promoter Methylation | Protein level correlation (Need anti-MGMT detection antibodies) |
Key Assay Strategy: Leveraging WT and C145A Mutant Proteins
For accurate inhibitor screening and resistance mechanism studies, TarMart offers both wild-type (WT) MGMT and the C145A catalytic-dead mutant. The C145A mutant serves as an essential negative control to confirm specific binding to the active-site cysteine. This pair enables robust competition assays (e.g., O6-benzylguanine displacement) and facilitates PROTAC degrader development by distinguishing occupancy from degradation. Combined with validated siRNA sets and lentiviral overexpression tools, researchers can build comprehensive cellular models to evaluate drug efficacy and specificity.